Ebola raises profile of blood-based therapy

Nature

Volumn 517, Issue 7532, 2015, Pages 9-10

  Butler, Declan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; VACCINE; VIRUS ANTIBODY;

BLOOD; DISEASE CONTROL; HEALTH CARE; HEALTH POLICY; INFECTIOUS DISEASE; PLASMA;

AVIAN INFLUENZA; AWARENESS; BLOOD DONOR; BLOOD TRANSFUSION; EBOLA HEMORRHAGIC FEVER; HUMAN; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMIC; PATHOGENESIS; PLASMA TRANSFUSION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEVERE ACUTE RESPIRATORY SYNDROME; SHORT SURVEY; SURVIVOR; ADOPTIVE TRANSFER; AFRICA; BLOOD; CLINICAL TRIAL (TOPIC); COMMUNICABLE DISEASES, EMERGING; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; PLASMA;

LIBERIA [WEST AFRICA];

ADOPTIVE TRANSFER; AFRICA, WESTERN; ANTIBODIES, VIRAL; BLOOD TRANSFUSION; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASES, EMERGING; HEMORRHAGIC FEVER, EBOLA; HUMANS; PLASMA; SURVIVORS;

EID: 84922480816     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/517009a     Document Type: Short Survey

References (3)

1. Luke, T. C. et al. Ann. Intern. Med. 145, 599-609 (2006).
2. Mair-Jenkins, J. et al. J. Infect. Dis. http://dx.doi.org/10.1093/infdis/jiu396 (2014).
3. Wu, J. T., Lee, C. K., Cowling, B. J. & Yuen, K. Y. Proc. Natl Acad. Sci. USA 107, 3269-3274 (2010).